Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Cash from Investing Activities (2016 - 2025)

Apyx Medical (APYX) has disclosed Cash from Investing Activities for 15 consecutive years, with -$275000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 12.24% year-over-year to -$275000.0, compared with a TTM value of -$1.1 million through Dec 2025, down 54.29%, and an annual FY2025 reading of -$1.1 million, down 54.29% over the prior year.
  • Cash from Investing Activities was -$275000.0 for Q4 2025 at Apyx Medical, up from -$519000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $7.1 million in Q2 2023 and bottomed at -$519000.0 in Q3 2025.
  • Average Cash from Investing Activities over 5 years is $158250.0, with a median of -$181000.0 recorded in 2022.
  • The sharpest move saw Cash from Investing Activities crashed 1788.89% in 2021, then surged 1873.32% in 2023.
  • Year by year, Cash from Investing Activities stood at -$332000.0 in 2021, then soared by 57.23% to -$142000.0 in 2022, then skyrocketed by 34.51% to -$93000.0 in 2023, then tumbled by 163.44% to -$245000.0 in 2024, then dropped by 12.24% to -$275000.0 in 2025.
  • Business Quant data shows Cash from Investing Activities for APYX at -$275000.0 in Q4 2025, -$519000.0 in Q3 2025, and -$265000.0 in Q2 2025.